<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983551</url>
  </required_header>
  <id_info>
    <org_study_id>190512</org_study_id>
    <nct_id>NCT03983551</nct_id>
  </id_info>
  <brief_title>Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas</brief_title>
  <official_title>Comparing the Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas on Urinary Albumin Excretion in People With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the
      treatment of type 2 diabetes mellitus (T2DM). Although both medications effectively lower
      plasma glucose levels, differences may exist in their pharmacokinetics and effect on the
      kidney. In the context of diabetic kidney disease, DPP-4 inhibitors may confer renal
      protection through several putative mechanisms. In contrast, sulfonylureas are associated
      with weight gain and cardiac dysfunction, which may adversely influence kidney function.

      The investigators hypothesize that DPP-4 inhibitors and sulfonylureas may have a different
      effect on the diabetic kidney. This study compares the effect of DPP-4 inhibitors and
      sulfonylureas on urinary albumin excretion in patients with newly diagnosed T2DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic kidney disease (DKD) occurs in a considerable number of individuals with type 2
      diabetes mellitus (T2DM). DKD leads to substantial morbidity and reduces the quality of life
      in afflicted patients. Chronic hyperglycemia induces proapoptotic signaling pathways in
      mesangial cells, leading to microvascular injury in the diabetic kidney. Clinical
      interventions targeting plasma glucose, body weight, and blood pressure have been shown to
      attenuate the progression of DKD.

      Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the
      treatment of T2DM. Although both medications effectively lower plasma glucose levels,
      differences may exist in their pharmacokinetics and effect on the kidney. In the context of
      DKD, DPP-4 inhibitors may confer renal protection through several putative mechanisms.
      However, whether such renal protection involves the glucose lowering efficacy of DPP-4
      inhibitors or additional mechanisms remains controversial. In contrast, currently there is
      inadequate information concerning the effect of sulfonylureas on the development of DKD. If
      the glucose lowering effect of DPP-4 inhibitors is a major determinant of renal protection,
      then sulfonylureas may theoretically offer similar benefit by maintaining euglycemia.
      However, sulfonylureas are associated with weight gain and cardiac dysfunction, which may
      adversely influence kidney function.

      Given that DPP-4 inhibitors and sulfonylureas have different effect on physiologic parameters
      including body weight and blood pressure, the investigators hypothesize that these
      medications may have different effects on the diabetic kidney. This study compares the effect
      of DPP-4 inhibitors and sulfonylureas on urinary albumin excretion in patients with newly
      diagnosed T2DM.

      In this study, patients with newly diagnosed T2DM are screened for eligibility. All
      participants receive 1000 mg of metformin therapy at the beginning of the study.
      Subsequently, patients are assigned to receive either the DPP-4 inhibitor Vildagliptin 50 mg
      twice daily or the sulfonylurea Glimepiride 2 mg twice daily. Treatment allocation is made by
      a committee of endocrinologists to match participants in the treatment groups by age, body
      weight, serum glycated hemoglobin (HbA1c), urinary albumin-to-creatinine ratio (ACR), and
      serum creatinine.

      At the initial clinic visit, participants receive blood tests for serum HbA1c, serum
      creatinine, serum alanine transferase, and plasma lipid profile after a 12-hour fast. Urine
      samples will be collected in the morning after a 12-hour fast, and urinary ACR is measured by
      the turbidimetric method. Laboratory tests for these clinical variables are repeated after 24
      weeks of pharmacologic treatment. Participants who loss follow up or withdraw from the study
      will be assessed by an intention to treat analysis. The change in urinary ACR is defined as
      the primary outcome measure, whereas changes in serum HbA1c, serum creatinine, body weight,
      and systolic blood pressure are considered secondary outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urinary albumin-to-creatinine ratio</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in urinary albumin-to-creatinine ratio after pharmacologic treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum glycated hemoglobin A1c</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in serum glycated hemoglobin A1c after pharmacologic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in body weight after pharmacologic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in serum creatinine after pharmacologic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in systolic blood pressure after pharmacologic treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Dipeptidyl peptidase 4 inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylureas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl Peptidase 4 Inhibitor</intervention_name>
    <description>Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily</description>
    <arm_group_label>Dipeptidyl peptidase 4 inhibitors</arm_group_label>
    <other_name>DPP-4 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea</intervention_name>
    <description>Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily</description>
    <arm_group_label>Sulfonylureas</arm_group_label>
    <other_name>SU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients exceeding 20 years of age

          -  Patients with newly diagnosed type 2 diabetes mellitus

          -  Patients who have yet to receive antidiabetic medications

        Exclusion Criteria:

          -  Patients with non-diabetic kidney disease

          -  Patients with congenital kidney abnormalities

          -  Patients with end stage renal disease.

          -  Patients who have received angiotensin-converting-enzyme inhibitor or angiotensin II
             receptor blocker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih Te Tu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Changhua Christian Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J. 2014 Aug;38(4):252-60. doi: 10.4093/dmj.2014.38.4.252. Review.</citation>
    <PMID>25215271</PMID>
  </reference>
  <reference>
    <citation>Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S3-21. doi: 10.1053/j.ajkd.2013.10.050. Review.</citation>
    <PMID>24461728</PMID>
  </reference>
  <reference>
    <citation>Mishra R, Emancipator SN, Kern T, Simonson MS. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int. 2005 Jan;67(1):82-93.</citation>
    <PMID>15610231</PMID>
  </reference>
  <reference>
    <citation>Kim MK. Treatment of diabetic kidney disease: current and future targets. Korean J Intern Med. 2017 Jul;32(4):622-630. doi: 10.3904/kjim.2016.219. Epub 2017 Jun 30. Review.</citation>
    <PMID>28704915</PMID>
  </reference>
  <reference>
    <citation>Introduction: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2. doi: 10.2337/dc18-Sint01.</citation>
    <PMID>29222369</PMID>
  </reference>
  <reference>
    <citation>Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract. 2013 Nov-Dec;19(6):1050-61. doi: 10.4158/EP12303.RA. Review.</citation>
    <PMID>24126227</PMID>
  </reference>
  <reference>
    <citation>Makino Y, Fujita Y, Haneda M. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):67-73. doi: 10.1097/MNH.0000000000000080. Review.</citation>
    <PMID>25415611</PMID>
  </reference>
  <reference>
    <citation>Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corlian√≤ F, Fra GP, Bartoli E, Derosa G. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015 Aug 12;11(4):840-8. doi: 10.5114/aoms.2015.53304. Epub 2015 Aug 11.</citation>
    <PMID>26322096</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhua Christian Hospital</investigator_affiliation>
    <investigator_full_name>Po-Chung Cheng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>dipeptidyl peptidase 4 inhibitors</keyword>
  <keyword>sulfonylureas</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data that underlie results in a publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Starting immediately after publication.</ipd_time_frame>
    <ipd_access_criteria>Available to any interested researcher.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

